Recently, while screening stocks for our Premium Members, I came across Prevest Denpro.
It’s a small dental materials and oral care company.
The dental industry continues to see steady demand across restorative, preventive, and digital dentistry segments. Export markets and technology-led product categories remain key growth areas.
Below are the key factual highlights regarding US plans, Digital Dentistry from the company’s H1 FY26 earnings conference call.
Help us grow: If you think our stock recommendations could add value to your friends, relatives, or acquaintances, we’d appreciate you spreading the word about Katalyst Wealth.
Before that: Here’s the list of new recommendations released by us in last few weeks
- For Insider Bets members – On 22nd Jan’26, we released our New stock report under “Insider Bets“ subscription. It’s a rare setup wherein Promoter is increasing stake via open market + preferential allotment, Valuations very reasonable at <10x earnings | <1x book and Earnings growth strong at 15%+ CAGR. You can access it by signing up HERE
- For Alpha/Alpha + members – On 31st Dec’25, we released a new long term investment recommendation for Alpha and Alpha + members. It’s a specialty products company which has delivered 20% + Sales and PAT CAGR, is net debt free, trading at attractive valuations with Price to Book value at 5 years low. You can access it by signing up HERE
Prevest Denpro – H1 FY26 Concall Highlights
Source: Prevest Denpro presentation
Financial Performance
H1 FY26
- Revenue from operations: ₹34.41 crore (+16.1% YoY)
- Total income: ₹36.77 crore (+16.6% YoY)
- EBITDA: ₹14.35 crore (+17.4% YoY)
- EBITDA margin: ~39.0%
- PBT: ₹13.36 crore (+18.4% YoY)
- PAT: ₹9.95 crore (+17.2% YoY)
- PAT margin: ~27.1%
Q2 FY26
- Revenue: ₹18.64 crore (+18.2% QoQ, +14.6% YoY)
- EBITDA: ₹7.87 crore (+21.5% QoQ)
- PAT growth YoY: ~15%
Domestic & Export Performance
- Export revenues grew ~24% YoY in H1 FY26
- Export recovery attributed to stabilization in countries earlier impacted by currency and regional disruptions
- Domestic growth in H1 was ~5%, impacted by:
- Temporary disruption due to regional disturbances in Jammu
- Flooding and heavy rains
- GST rate change (12% to 5%) leading to distributor realignment
- Q2 domestic growth rebounded strongly:
- ~19% QoQ
- ~13% YoY
- Management indicated double-digit domestic growth expected in H2
Digital Dentistry & New Products
- Digital dentistry identified as a key medium-term growth driver
- Progress across:
- 3D resins
- In-house assembly of 3D dental printers
- Scanners (under development)
- Installed resin capacity: 3,000 kg/month
- Current utilisation: <5%
- Capacity sufficient for next ~5 years
- Sales channels include:
- Dealers
- Direct sales to dentists
- E-commerce platform
- Conferences and on-spot bookings
- Bundled offering of printers + resins to ensure compatibility
US Market (Axiodent Subsidiary)
- US revenues grew ~43–47% YoY in H1
- Growth driven by:
- Private-label manufacturing
- Own-brand sales under Axiodent
- Tariff impact addressed through price realignment with customers
- Buyers partially absorbing tariff impact
- Management expects continued growth despite tariff-related challenges
Product Portfolio Updates
- Rotoflex rotary endodontic files:
- Strong acceptance
- Repeat demand visible
- Disinfectant range:
- Commercialized during the year
- Early traction reported
- Oradox oral care:
- Gradual improvement in consumer traction
- Expanded hiring to support scale-up
- Biomaterials:
- Existing biomaterials contributing to revenue
- New biomaterial-based products (including bone grafting materials) under development
Margins & Cost Structure
- Management reiterated focus on value-added, high-margin products
- Operating expenses controlled despite addition of new product lines
- Margins maintained through:
- Product mix optimization
- Cost discipline
- In-house R&D and import substitution strategy
Growth Outlook (as stated in concall)
- Management expects:
- >20% growth in H2 FY26
- Sustained export momentum
- US growth to continue
- Medium-term:
- Management indicated ~15% annual growth
- Target to cross ₹100 crore revenue within ~3 years
- Margins expected to be maintained as scale improves
Hope you found the blog post useful and it added value to your investment decisions. Sign up for more interesting stock ideas and industry notes.
Disclaimer: This is not a recommendation to buy/sell any of the stocks mentioned above. The securities quoted are for illustration only and are not recommendatory.
Ekansh Mittal
Research Analyst
SEBI Research Analyst Registration No. INH100001690
Research Analyst Details
Name: Ekansh Mittal Email Id: [email protected] Ph: +91 727 5050062
Details of Associate: Not Applicable
Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.
Disclaimer: http://www.
Registered Address – 7, Panch Ratan, 7/128, Swaroop Nagar, Kanpur – 208002
Place of Business – 205, Ratan Floor, 113/120, Swaroop Nagar, Kanpur – 208002
Compliance Officer/Grievance Redressal – Mr. Ekansh Mittal, +91-9818866676, info@
“Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors”.
“Investment in securities market are subject to market risks. Read all the related documents carefully before investing.”
The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision
This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.
The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report.
We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis.
Use of Artificial Intelligence: RA may infrequently use Artificial Intelligence (AI) tools like chatgpt, notebooklm, etc. in its research services to enhance the quality and efficiency of the recommendations provided to clients. The tools are primarily used for data collection and generating con-call summaries for the purpose of research.
In accordance with Regulation 24(7) of the SEBI (Research Analyst) Regulations, 2014: We take full responsibility for the security, confidentiality, and integrity of client data used in conjunction with AI tools and we ensure compliance with applicable laws regarding the use of AI tools.
Disclaimer: You can access it here – LINK
Whether the research analyst or research entity or his associate or his relative has any financial interest in the subject company/companies and the nature of such financial interest – No
Whether the research analyst or research entity or his associates or his relatives have actual/beneficial ownership of 1% or more securities of the subject company (at the end of the month immediately preceding the date of publication of the research report or date of the public appearance) – No
Whether the research analyst or research entity or his associate or his relative has any other material conflict of interest at the time of publication of the research report or at the time of public appearance – No
Whether it or its associates have received any compensation from the subject company in the past twelve months – No
Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past 12 months – No
Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months – No
Whether the subject company is or was a client during twelve months preceding the date of distribution of the research report and the types of services provided – No
Whether the research analyst has served as an officer, director or employee of the subject company – No
Whether the research analyst or research entity has been engaged in market making activity for the subject company – No